S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.59 (+1.03%)
AAPL   179.89 (+1.49%)
MSFT   331.10 (+0.83%)
META   271.00 (+2.37%)
GOOGL   123.25 (+0.31%)
AMZN   122.66 (+1.72%)
TSLA   206.14 (+1.08%)
NVDA   394.40 (+4.24%)
NIO   7.56 (+0.40%)
BABA   83.10 (+4.46%)
AMD   120.07 (+1.57%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.16 (+1.41%)
CGC   0.84 (+0.93%)
GE   104.68 (+3.10%)
DIS   88.85 (+1.01%)
AMC   4.61 (+2.44%)
PFE   38.04 (+0.05%)
PYPL   63.18 (+1.92%)
NFLX   403.45 (+2.08%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.59 (+1.03%)
AAPL   179.89 (+1.49%)
MSFT   331.10 (+0.83%)
META   271.00 (+2.37%)
GOOGL   123.25 (+0.31%)
AMZN   122.66 (+1.72%)
TSLA   206.14 (+1.08%)
NVDA   394.40 (+4.24%)
NIO   7.56 (+0.40%)
BABA   83.10 (+4.46%)
AMD   120.07 (+1.57%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.16 (+1.41%)
CGC   0.84 (+0.93%)
GE   104.68 (+3.10%)
DIS   88.85 (+1.01%)
AMC   4.61 (+2.44%)
PFE   38.04 (+0.05%)
PYPL   63.18 (+1.92%)
NFLX   403.45 (+2.08%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.59 (+1.03%)
AAPL   179.89 (+1.49%)
MSFT   331.10 (+0.83%)
META   271.00 (+2.37%)
GOOGL   123.25 (+0.31%)
AMZN   122.66 (+1.72%)
TSLA   206.14 (+1.08%)
NVDA   394.40 (+4.24%)
NIO   7.56 (+0.40%)
BABA   83.10 (+4.46%)
AMD   120.07 (+1.57%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.16 (+1.41%)
CGC   0.84 (+0.93%)
GE   104.68 (+3.10%)
DIS   88.85 (+1.01%)
AMC   4.61 (+2.44%)
PFE   38.04 (+0.05%)
PYPL   63.18 (+1.92%)
NFLX   403.45 (+2.08%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.59 (+1.03%)
AAPL   179.89 (+1.49%)
MSFT   331.10 (+0.83%)
META   271.00 (+2.37%)
GOOGL   123.25 (+0.31%)
AMZN   122.66 (+1.72%)
TSLA   206.14 (+1.08%)
NVDA   394.40 (+4.24%)
NIO   7.56 (+0.40%)
BABA   83.10 (+4.46%)
AMD   120.07 (+1.57%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.16 (+1.41%)
CGC   0.84 (+0.93%)
GE   104.68 (+3.10%)
DIS   88.85 (+1.01%)
AMC   4.61 (+2.44%)
PFE   38.04 (+0.05%)
PYPL   63.18 (+1.92%)
NFLX   403.45 (+2.08%)
NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Forecast, Price & News

$0.23
+0.01 (+3.14%)
(As of 12:06 PM ET)
Compare
Today's Range
$0.22
$0.24
50-Day Range
$0.19
$0.24
52-Week Range
$0.19
$2.09
Volume
112,293 shs
Average Volume
978,402 shs
Market Capitalization
$8.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Catalyst Biosciences MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.62mentions of Catalyst Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.16) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars


CBIO stock logo

About Catalyst Biosciences (NASDAQ:CBIO) Stock

Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.

Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Stock News Headlines

ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
5 Cheap Healthcare Stocks to Buy in 2023
AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
12 Cheap Healthcare Stocks to Buy in 2023
Catalyst Biosciences Provides Corporate Update
Catalyst/Millburn Hedge Strategy I
5 Stocks with the Lowest PE Ratio
CBIO Catalyst Biosciences, Inc.
See More Headlines

CBIO Price History

CBIO Company Calendar

Last Earnings
11/12/2021
Today
6/01/2023
Next Earnings (Estimated)
6/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
Employees
56
Year Founded
2003

Profitability

Net Income
$-8,240,000.00
Pretax Margin
-994.21%

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
36,250,000
Market Cap
$8.69 million
Optionable
Optionable
Beta
0.90

Social Links


Key Executives

  • Nassim Usman
    President, Chief Executive Officer & Director
  • Seline E. Miller
    Chief Financial & Accounting Officer
  • Tom Knudsen
    Senior Vice President-Strategy & Development
  • Trisha Colton
    Head-Investor Relations













CBIO Stock - Frequently Asked Questions

How have CBIO shares performed in 2023?

Catalyst Biosciences' stock was trading at $0.5275 at the beginning of the year. Since then, CBIO stock has decreased by 56.4% and is now trading at $0.2301.
View the best growth stocks for 2023 here
.

Are investors shorting Catalyst Biosciences?

Catalyst Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 322,400 shares, an increase of 52.3% from the April 30th total of 211,700 shares. Based on an average trading volume of 901,400 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.3% of the shares of the company are sold short.
View Catalyst Biosciences' Short Interest
.

When is Catalyst Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023.
View our CBIO earnings forecast
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.14. The biopharmaceutical company earned $2.30 million during the quarter, compared to the consensus estimate of $1 million.

How often does Catalyst Biosciences pay dividends? What is the dividend yield for Catalyst Biosciences?

Catalyst Biosciences declared a dividend on Wednesday, January 4th. Investors of record on Monday, January 16th will be paid a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date of this dividend is Friday, January 13th.
Read our dividend analysis for CBIO
.

When did Catalyst Biosciences' stock split?

Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.32%), Acadian Asset Management LLC (0.69%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $0.23.

How much money does Catalyst Biosciences make?

Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $8.69 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-8,240,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107.

This page (NASDAQ:CBIO) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -